To qualify for the TGCT trial, the patient must:
This is not a complete list of participation criteria and other inclusion/exclusion criteria may apply.
By enrolling in this Phase I trial:
You could potentially see effects of the study drug on your:
You will help us understand:
Your participation in this study will help researchers and doctors better understand DCC-3014 and its potential effects. This information may also benefit others with your condition in the future.
i'm interestedThis study focuses on patients living with Tenosynovial Giant Cell Tumor (TGCT), also known as Pigmented Villonodular Synovitis (PVNS). This trial will study the effectiveness and safety of an investigational oral study drug (called “DCC-3014”) by assessing the drug's effects on your tumor response, range of motion (ROM), physical function and pain.
The study doctor and study team will be available to answer any questions that you or your family might have.